A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report

• Published in: Stem cell research & therapy Vol. 11; no. 1; pp. 1 - 291
• Main Authors: Peng, Hongbing, Gong, Tiefeng, Huang, Xiaoying, Sun, Xun, Luo, Hong, Wang, Weizhong, Luo, Junbiao, Luo, Baowei, Chen, Yanhui, Wang, Xingxing, Long, Haifeng, Mei, Hua, Li, Chuang, Dai, Yanni, Li, Honghui
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 16.07.2020; BioMed Central; BMC
• Subjects: Acute respiratory distress syndrome; Antibodies; Antiviral agents; Biological response modifiers; Blood pressure; Care and treatment; Cell number; Convalescent plasma; Coronavirus disease 2019; Coronaviruses; COVID-19; Cytokine storm; Cytokines; Dyspnea; Engineering research; Health aspects; Hepatitis; Illnesses; Infectious diseases; Inflammation; Interferon; Intravenous administration; Laboratories; Lopinavir; Lymphocytes; Medical prognosis; Medical research; Meropenem; Mesenchymal stem cells; Methylprednisolone; Mortality; Multiple organ dysfunction syndrome; Neutrophils; Oxygen saturation; Patients; Plasma; Public health; Respiratory distress syndrome; Respiratory function; Ribavirin; Ritonavir; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Short Report; Stem cell research; Stem cells; Umbilical cord; Viruses; α-Interferon; China
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-020-01802-8

Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-[alpha], and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies. Keywords: Convalescent plasma, Mesenchymal stem cells, Coronavirus disease 2019, COVID-19, SARS-CoV-2